ELISA kit GHRH,GHRH,GRF,Growth hormone-releasing factor,Growth hormone-releasing hormone,Pig,Somatoliberin,Sus scrofa
- Known as:
- Enzyme-linked immunosorbent assay test reagent GHRH,GHRH,GRF,Growth hormone-releasing factor,Growth hormone-releasing hormone,Pig,Somatoliberin,Sus scrofa
- Catalog number:
- E0438p
- Product Quantity:
- 96T
- Category:
- -
- Supplier:
- EIAab
- Gene target:
- ELISA kit GHRH GRF Growth hormone-releasing factor hormone Pig Somatoliberin Sus scrofa
Related genes to: ELISA kit GHRH,GHRH,GRF,Growth hormone-releasing factor,Growth hormone-releasing hormone,Pig,Somatoliberin,Sus scrofa
- Gene:
- GHRH NIH gene
- Name:
- growth hormone releasing hormone
- Previous symbol:
- GHRF
- Synonyms:
- -
- Chromosome:
- 20q11.23
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-10-05
Related products to: ELISA kit GHRH,GHRH,GRF,Growth hormone-releasing factor,Growth hormone-releasing hormone,Pig,Somatoliberin,Sus scrofa
Related articles to: ELISA kit GHRH,GHRH,GRF,Growth hormone-releasing factor,Growth hormone-releasing hormone,Pig,Somatoliberin,Sus scrofa
- Pancreatic GHRHomas (pGHRHomas) with acromegaly have unique conditions, harboring the existence of multiple endocrine neoplasia type 1 (MEN 1). Moreover, pituitary lesions are affected by both protracted ectopic GHRH and loss of menin function. Of significance is the clarification of clinicopathological aspects of pGHRHomas in patients with or without MEN 1. From 1977-2016, thirty-six patients with pGHRHomas were reported. Twenty-two out of 36 patients (61%) had pGHRHomas with MEN 1 and 14 patients did not. The former had a tendency of male predominance, benign tumor behavior and fewer metastasis rather than the latter. The latter is a single pGHRHoma accompanied by pituitary enlargement with somatotroph hyperplasia (hyperplasia) caused by protracted ectopic GHRH. Nine patients with MEN 1 underwent transsphenoidal surgery (TSS). The hyperplasia associated with various pituitary adenomas (PAs) including three GH-related adenomas was observed in seven subjects (32%). In these patients, the resection of their pGHRHomas was feasible. Furthermore, all patients with acromegaly due to pGHRHomas without MEN 1 had non-TSS, whereas approximately 70% of those with MEN 1 had unnecessary TSS. The association with hyperplasia and various PAs suggested that formation of the three GH-related adenomas may be induced by the foundations of MEN 1 gene mutations. J. Med. Invest. 71 : 1-8, February, 2024. - Source: PubMed
Yamasaki Ryuichi - The separation between the inside and outside through the skin was fundamental for the evolution of prevertebrates, which grow through extrapituitary circuits, to vertebrates, which grow through the somatotrophic axis, namely pituitary growth hormone (GH). and circulating IGF1.Individuals with untreated isolated growth hormone (GH) deficiency (IGHD) due to a mutation in the GH-releasing hormone receptor (GHRH) gene, residing in Itabaianinha, Brazil, are vulnerable to skin cancer and have reduced sweating. However other aspects of their skin physiology are still unknown. Our objectives were to evaluate the number of skin cancers, skin aging, and functional aspects of the skin in this IGHD cohort. - Source: PubMed
Publication date: 2024/05/04
Barros-Oliveira Cynthia Sde Jesus Maria Joseli MeloCampos Viviane CSalvatori Robertode Souza Araújo Adriano AntunesNeto Roberto Fernandes SoaresBartke AndrzejBatista Vanderlan OSchneider AugustoVillar-Gouy Keila RMasternak Michal MLeal Ângela CSantos Lucas BOliveira Carla R PSantos Elenilde GOliveira Simões Davi Ade Santana Silva BrunoAguiar-Oliveira Manuel H - Pituitary gigantism is a rare manifestation of chronic growth hormone (GH) excess that begins before closure of the growth plates. Nearly half of pituitary gigantism patients have an identifiable genetic cause. X-linked acrogigantism (X-LAG; 10% of pituitary gigantism) typically begins during infancy and can lead to the tallest individuals described. In the 10 years since its discovery, about 40 patients have been identified. Patients with X-LAG usually develop mixed GH and prolactin macroadenomas with occasional hyperplasia that secrete copious amounts of GH, and frequently prolactin. Circulating GH releasing hormone (GHRH) is also elevated in a proportion of patients. X-LAG is caused by constitutive or sporadic mosaic duplications at chromosome Xq26.3 that disrupt the normal chromatin architecture of a topologically associating domain (TAD) around the orphan G protein coupled receptor (GPCR), GPR101. This leads to the formation of a neoTAD in which GPR101 over-expression is driven by ectopic enhancers ("TADopathy"). X-LAG has been seen in three families due to transmission of the duplication from affected mothers to sons. GPR101 is a constitutively active receptor with an unknown natural ligand that signals via multiple G proteins and protein kinases A and C to promote GH/prolactin hypersecretion. Treatment of X-LAG is challenging due to the young patient population and resistance to somatostatin analogs; the GH receptor antagonist pegvisomant is often an effective option. GH, insulin-like growth factor 1 (IGF-1) and prolactin hypersecretion and physical overgrowth can be controlled before definitive adult gigantism occurs, often at the cost of permanent hypopituitarism. - Source: PubMed
Publication date: 2024/05/02
Daly Adrian FBeckers Albert - This study was conducted to investigate the variants of the growth hormone receptor (GHR), growth hormone-releasing hormone (GHRH), pituitary-specific transcription factor-1 (PIT1), and signal transducer and activator of transcription 5A (STAT5) genes and their effect on growth performance and dressing percentage (DP) parameters. - Source: PubMed
Publication date: 2024/03/31
Agung Paskah PartogiSaputra FerdyPutra Widya Pintaka BayuSaid SyahruddinZein Moch Syamsul ArifinHarianja Febrina HastutiSudiro Aditya - The effect of growth hormone-releasing hormone (GHRH) plasmid treatment on sow reproductive performance was examined. Forty pregnant sows (three-way crossbreed: Landrace × Yorkshire × Duroc) at 85 days of gestation were included in the study and consisted of twenty primiparous and twenty multiparous sows (third parity). Sows were randomly assigned to the control and treatment groups. The treatment group received 5 mg dose of GHRH plasmid injection via electroporation, whereas the control group received a phosphate buffer solution. Reproductive indicators, including serum insulin-like growth factor-1 (IGF-1) concentration and weaned piglet data, were assessed. In the GHRH plasmid-treated group, serum IGF-1 concentration significantly increased compared with that in the control group, a trend observed in primiparous and multiparous sows. The key indicator of reproductive performance, litter size, showed that for control primiparous sows (C-PS), it was 10.90 ± 0.99 kg, while for control multiparous sows (C-MS), it was 14.00 ± 0.67 kg. Furthermore, for primiparous sows treated with GHRH plasmid (G-PS), the litter size was 11.60 ± 0.97 kg, and for multiparous sows treated with GHRH plasmid (G-MS), it was 14.00 ± 0.82 kg. The GHRH plasmid-treated group also exhibited a higher number of total births and surviving piglet numbers, along with a decrease in stillborn piglets; however, there was no significant difference in birth weight. The results suggest that GHRH plasmid treatment can enhance the reproductive performance of sows. - Source: PubMed
Publication date: 2024/04/10
Kim Min JungPark Ji-YongCho Chang-SooYang Ye JinHeo Ji WoongKim Woo HLee Hu-JangPark Kwang Il